Ransom Advisory Ltd Has $1.38 Million Stock Holdings in CVS Health Corporation $CVS

Ransom Advisory Ltd lessened its stake in shares of CVS Health Corporation (NYSE:CVS) by 8.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,021 shares of the pharmacy operator’s stock after selling 1,789 shares during the period. Ransom Advisory Ltd’s holdings in CVS Health were worth $1,381,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bell Investment Advisors Inc grew its holdings in CVS Health by 119.8% during the first quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 248 shares during the last quarter. Roxbury Financial LLC grew its stake in shares of CVS Health by 78.3% in the second quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 202 shares during the last quarter. Saudi Central Bank acquired a new stake in shares of CVS Health in the first quarter worth $34,000. Livelsberger Financial Advisory acquired a new stake in shares of CVS Health in the second quarter worth $35,000. Finally, Costello Asset Management INC grew its stake in shares of CVS Health by 281.3% in the first quarter. Costello Asset Management INC now owns 572 shares of the pharmacy operator’s stock worth $39,000 after acquiring an additional 422 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Stock Up 0.4%

Shares of NYSE CVS opened at $75.00 on Monday. The stock has a market cap of $95.12 billion, a PE ratio of 20.95, a PEG ratio of 0.83 and a beta of 0.62. The business has a fifty day moving average of $67.11 and a two-hundred day moving average of $66.33. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $75.55. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. The company had revenue of $98.92 billion during the quarter, compared to analysts’ expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business’s revenue was up 8.4% on a year-over-year basis. During the same period last year, the business earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is presently 74.30%.

Insider Activity

In related news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.22% of the company’s stock.

Wall Street Analyst Weigh In

CVS has been the topic of several research analyst reports. Cowen restated a “buy” rating on shares of CVS Health in a research note on Monday, August 4th. Baird R W upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. UBS Group upgraded shares of CVS Health from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $67.00 to $79.00 in a research note on Monday, August 18th. Morgan Stanley lifted their price target on shares of CVS Health from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Friday, August 1st. Finally, Robert W. Baird upgraded shares of CVS Health from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $71.00 to $82.00 in a research note on Thursday, August 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $77.89.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.